Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study

What Was Tested

The paper reports a study of Peptide YY and Oxyntomodulin, published as a randomized controlled trial.

Roux-en-Y gastric bypass (RYGB) augments postprandial secretion of glucagon-like peptide 1 (GLP-1), oxyntomodulin (OXM), and peptide YY (PYY).

Their objective was to study the effects of GOP on glycemia and body weight when given for 4 weeks to patients with diabetes and obesity.

Who Took Part

According to the abstract, 4 patients were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In this single-blinded mechanistic study, obese patients with prediabetes/diabetes were randomized to GOP (n = 15) or saline (n = 11) infusion for 4 weeks.

How the Study Was Run

The design is described as randomized and single-blind.

The patients were allocated by chance, so the Peptide YY group and the comparison group should start out alike.

In this single-blind Peptide YY study one party knew the assignments and the other did not.

A time span of 4 weeks appears in the methods.

Outcomes measured were 1) body weight, 2) fructosamine levels, 3) glucose and insulin during a mixed meal test (MMT), 4) energy expenditure (EE), 5) energy intake (EI), and 6) mean glucose and measures of glucose variability during continuous glucose monitoring.

What Was Measured

The subject headings attached to it are Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Hypoglycemia, Infusions, Subcutaneous and Insulin.

What This Means in Plain Language

The paper is a randomized and single-blind study of Peptide YY and Oxyntomodulin in 4 patients over 4 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Diabetes care), a journal based in United States.

More context: the Peptide YY compound page and the Oxyntomodulin compound page, all human trials.